City Chic (ASX:CCX) share price to grab attention after HY21 profit growth fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.
3 little known ASX growth shares to buy
Tristan Harrison | February 21, 2021 9:37am |
More on: Image source: Getty Images
There are a number of smaller businesses on the ASX that aren’t well known but may be able to make good returns for investors.
It is usually easier for a business to double from $500 million to $1 billion than it is to go from $5 billion to $10 billion because of the difficulty of doubling bigger and bigger numbers.
That’s why these ASX growth shares could be worth thinking about:
This business is a global retailer of plus-size clothes, footwear and accessories for women. Not only does City Chic have a large network of retail stores across Australia and New Zealand, but it also has wholesale agreements in the northern hemisphere and a website in the US.
The ASX small cap with the best global expansion potential may not be tech
Brendon Lau | February 1, 2021 4:30pm |
More on:
The outrageous success of the
Afterpay Ltd(ASX: APT) has investors scrambling to find the next emerging ASX stock with global potential.
It turns out that the ASX small cap that holds the key may not be a sexy tech or fintech related start-up.
Morgan Stanley looked through its small cap universe of stocks and picked the
City Chic Collective Ltd(ASX: CCX) share price as its preferred global expansion story.
The best ASX small cap global expansion opportunity
City Chic is a leading women’s plus-size apparel retailer in Australia but the broker reckons the global revenue opportunity stands at around US$60 billion.
2 exciting small cap ASX shares to buy
Tristan Harrison | January 16, 2021 11:45am |
More on:
Some small cap ASX shares may be able to make good returns over the longer-term.
There are smaller businesses that have interesting characteristics, which may be of interest to some investors:
Volpara is a medical technology business. Its main service is providing software to help detect breast cancer early on by increasing the quality of screening using AI.
The small cap ASX share reported its FY21 half-year result a couple of months ago. Subscription revenue went up 71% to NZ$8.8 million, though total revenue only grew by 38% to NZ$9.5 million. Annual recurring revenue (ARR) went up from NZ$18 million to NZ$19.9 million.